Imricor Completes Successful A$60 Million Capital Raise

• Raised A$60 million (US$43.2 million) via a placement to new and existing institutional, sophisticated and professional investors
• Proceeds will be used to accelerate Imricor's growth strategy, including launching NorthStar in the U.S. and advancing regulatory approvals
• Company expects to have cash reserves of approximately A$102.9 million (US$74.1 million) after the placement

Imricor Medical Systems, Inc. (ASX: IMR) has received firm commitments to raise A$60.0 million (US$43.2 million) via a placement to new and existing institutional, sophisticated and professional investors. The placement was completed at an offer price of A$1.85 per CHESS Depositary Interest (CDI), representing a 6.3% discount to the company's last traded price. Proceeds from the placement will be used to accelerate Imricor's growth strategy, including launching NorthStar in the U.S., advancing regulatory approvals for the full Electrophysiology (EP) platform, completing key clinical programs, progressing Pulsed Field Ablation (PFA) development, and supporting expansion in the Middle East and other target markets. Following the raise, the company expects to have cash reserves of approximately A$102.9 million (US$74.1 million) after costs. Imricor's Chair and CEO, Steve Wedan, commented that the capital raise gives the company the financial strength to move decisively from momentum to scale, with NorthStar now cleared in the U.S., the pediatric label expansion submitted, and the broader EP platform continuing to advance through the FDA process.

The company expects to have cash reserves of approximately A$102.9 million (US$74.1 million) after costs following completion of the Placement.

Imricor is well capitalised to execute on its commercial, clinical and regulatory objectives, including launching NorthStar in the U.S., advancing regulatory approvals for the full Electrophysiology platform, completing key clinical programs, progressing Pulsed Field Ablation development, and supporting expansion in the Middle East and other target markets.